Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:97-101

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zou, Y.
Right arrow Articles by Komuro, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zou, Y.
Right arrow Articles by Komuro, I.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Hypertrophy

(Circulation. 2001;104:97.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Calcineurin Plays a Critical Role in the Development of Pressure Overload–Induced Cardiac Hypertrophy

Yunzeng Zou, MD, PhD; Yukio Hiroi, MD, PhD; Hiroki Uozumi, MD; Eiki Takimoto, MD; Haruhiro Toko, MD; Weidong Zhu, MD, PhD; Sumiyo Kudoh, MD, PhD; Miho Mizukami, MD; Masaki Shimoyama, MD, PhD; Futoshi Shibasaki, PhD; Ryozo Nagai, MD, PhD; Yoshio Yazaki, MD, PhD; Issei Komuro, MD, PhD

From the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba (Y.Z., H.T., M.M., I.K.); the Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo (Y.H., H.U., E.T., W.Z., S.K., M.S., R.N.); Tokyo Metropolitan Institute of Medical Science, Tokyo (F.S.); and the International Medical Center of Japan, Tokyo (Y.Y.), Japan.

Correspondence to Issei Komuro, MD, PhD, Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. E-mail komuro-tky{at}umin.ac.jp

Background—Although activation of the Ca2+-dependent phosphatase calcineurin has been reported to induce cardiomyocyte hypertrophy, whether calcineurin is involved in pressure overload–induced cardiac hypertrophy remains controversial.

Methods and Results—We examined in the present study the role of calcineurin in pressure overload–induced cardiac hypertrophy using transgenic mice that overexpress the dominant negative mutant of calcineurin specifically in the heart. There were no significant differences in body weight, blood pressure, heart rate, heart weight, and the cardiac calcineurin activity between the transgenic mice and their littermate wild-type mice at basal state. The activity of calcineurin was markedly increased by pressure overload produced by constriction of the abdominal aorta in the heart of wild-type mice but less increased in the heart of the transgenic mice. Pressure overload induced increases in heart weight, wall thickness of the left ventricle, and diameter of cardiomyocytes; reprogramming of expressions of immediate early response genes and fetal-type genes; activation of extracellular signal–regulated protein kinases; and fibrosis. All these hypertrophic responses were more prominent in the wild-type mice than in the transgenic mice.

Conclusions—These results suggest that calcineurin plays a critical role in the development of pressure overload–induced cardiac hypertrophy.


Key Words: calcineurin • hypertrophy • genes • pressure




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. C. Kolwicz, S. M. MacDonnell, B. F. Renna, P. O. Reger, R. Seqqat, K. Rafiq, Z. V. Kendrick, S. R. Houser, A. Sabri, and J. R. Libonati
Left ventricular remodeling with exercise in hypertension
Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1361 - H1368.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. M. MacDonnell, J. Weisser-Thomas, H. Kubo, M. Hanscome, Q. Liu, N. Jaleel, R. Berretta, X. Chen, J. H. Brown, A.-K. Sabri, et al.
CaMKII Negatively Regulates Calcineurin-NFAT Signaling in Cardiac Myocytes
Circ. Res., August 14, 2009; 105(4): 316 - 325.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. M. Cereghetti, A. Stangherlin, O. M. de Brito, C. R. Chang, C. Blackstone, P. Bernardi, and L. Scorrano
Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria
PNAS, October 14, 2008; 105(41): 15803 - 15808.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Bourajjaj, A.-S. Armand, P. A. da Costa Martins, B. Weijts, R. van der Nagel, S. Heeneman, X. H. Wehrens, and L. J. De Windt
NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart Failure
J. Biol. Chem., August 8, 2008; 283(32): 22295 - 22303.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Takeda, E. Suzuki, M. Takahashi, S. Oba, H. Nishimatsu, K. Kimura, T. Nagano, R. Nagai, and Y. Hirata
Calcineurin is critical for sodium-induced neointimal formation in normotensive and hypertensive rats
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2871 - H2878.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S.-Y. Kim, R. Gul, S.-Y. Rah, S. H. Kim, S. K. Park, M.-J. Im, H. J. Kwon, and U.-H. Kim
Molecular mechanism of ADP-ribosyl cyclase activation in angiotensin II signaling in murine mesangial cells
Am J Physiol Renal Physiol, April 1, 2008; 294(4): F982 - F989.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. M. MacDonnell, H. Kubo, D. M. Harris, X. Chen, R. Berretta, M. F. Barbe, S. Kolwicz, P. O. Reger, A. Eckhart, B. F. Renna, et al.
Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3122 - H3129.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Cheng, R. Ji, J. Yue, J. Yang, X. Liu, H. Chen, D. B. Dean, and C. Zhang
MicroRNAs Are Aberrantly Expressed in Hypertrophic Heart: Do They Play a Role in Cardiac Hypertrophy?
Am. J. Pathol., June 1, 2007; 170(6): 1831 - 1840.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H.-J. Li, H. Yin, Y.-Y. Yao, B. Shen, M. Bader, L. Chao, and J. Chao
Tissue kallikrein protects against pressure overload-induced cardiac hypertrophy through kinin B2 receptor and glycogen synthase kinase-3{beta} activation
Cardiovasc Res, January 1, 2007; 73(1): 130 - 142.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
Y. J. Kang
Cardiac Hypertrophy: A Risk Factor for QT-Prolongation and Cardiac Sudden Death
Toxicol Pathol, January 1, 2006; 34(1): 58 - 66.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Tokudome, T. Horio, I. Kishimoto, T. Soeki, K. Mori, Y. Kawano, M. Kohno, D. L. Garbers, K. Nakao, and K. Kangawa
Calcineurin-Nuclear Factor of Activated T Cells Pathway-Dependent Cardiac Remodeling in Mice Deficient in Guanylyl Cyclase A, a Receptor for Atrial and Brain Natriuretic Peptides
Circulation, June 14, 2005; 111(23): 3095 - 3104.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Bubikat, L. J. De Windt, B. Zetsche, L. Fabritz, H. Sickler, D. Eckardt, A. Godecke, H. A. Baba, and M. Kuhn
Local Atrial Natriuretic Peptide Signaling Prevents Hypertensive Cardiac Hypertrophy in Endothelial Nitric-oxide Synthase-deficient Mice
J. Biol. Chem., June 3, 2005; 280(22): 21594 - 21599.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. Sanna, O. F. Bueno, Y.-S. Dai, B. J. Wilkins, and J. D. Molkentin
Direct and Indirect Interactions between Calcineurin-NFAT and MEK1-Extracellular Signal-Regulated Kinase 1/2 Signaling Pathways Regulate Cardiac Gene Expression and Cellular Growth
Mol. Cell. Biol., February 1, 2005; 25(3): 865 - 878.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. D Molkentin
Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs
Cardiovasc Res, August 15, 2004; 63(3): 467 - 475.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill
Hypertrophy of the Heart: A New Therapeutic Target?
Circulation, April 6, 2004; 109(13): 1580 - 1589.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. van Rooij, P. A. Doevendans, H. J.G.M. Crijns, S. Heeneman, D. J. Lips, M. van Bilsen, R. S. Williams, E. N. Olson, R. Bassel-Duby, B. A. Rothermel, et al.
MCIP1 Overexpression Suppresses Left Ventricular Remodeling and Sustains Cardiac Function After Myocardial Infarction
Circ. Res., February 20, 2004; 94 (3): e18 - e26.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. B. Vega, R. Bassel-Duby, and E. N. Olson
Control of Cardiac Growth and Function by Calcineurin Signaling
J. Biol. Chem., September 26, 2003; 278(39): 36981 - 36984.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Li, A. Yatani, S.-J. Kim, G. Takagi, K. Irie, Q. Zhang, V. Karoor, C. Hong, G. Yang, J. Sadoshima, et al.
Neurally-mediated increase in calcineurin activity regulates cardiac contractile function in absence of hypertrophy
Cardiovasc Res, September 1, 2003; 59(3): 649 - 657.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
W. Schubert, X. Y. Yang, T. T.C. Yang, S. M. Factor, M. P. Lisanti, J. D. Molkentin, M. Rincon, and C.-W. Chow
Requirement of transcription factor NFAT in developing atrial myocardium
J. Cell Biol., June 9, 2003; 161(5): 861 - 874.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
W. T. Pu, Q. Ma, and S. Izumo
NFAT Transcription Factors Are Critical Survival Factors That Inhibit Cardiomyocyte Apoptosis During Phenylephrine Stimulation In Vitro
Circ. Res., April 18, 2003; 92(7): 725 - 731.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. van Rooij, P. A. Doevendans, C. C. de Theije, F. A. Babiker, J. D. Molkentin, and L. J. De Windt
Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy
J. Biol. Chem., December 6, 2002; 277(50): 48617 - 48626.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
B. J. Wilkins, L. J. De Windt, O. F. Bueno, J. C. Braz, B. J. Glascock, T. F. Kimball, and J. D. Molkentin
Targeted Disruption of NFATc3, but Not NFATc4, Reveals an Intrinsic Defect in Calcineurin-Mediated Cardiac Hypertrophic Growth
Mol. Cell. Biol., November 1, 2002; 22(21): 7603 - 7613.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. Fatkin and R. M. Graham
Molecular Mechanisms of Inherited Cardiomyopathies
Physiol Rev, October 1, 2002; 82(4): 945 - 980.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Wang, G. W. De Keulenaer, E. O. Weinberg, S. Muangman, A. Gualberto, K. T. Landschulz, T. G. Turi, J. F. Thompson, and R. T. Lee
Direct biomechanical induction of endogenous calcineurin inhibitor Down Syndrome Critical Region-1 in cardiac myocytes
Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H533 - H539.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Nagata, F. Somura, K. Obata, M. Odashima, H. Izawa, S. Ichihara, T. Nagasaka, M. Iwase, Y. Yamada, N. Nakashima, et al.
AT1 Receptor Blockade Reduces Cardiac Calcineurin Activity in Hypertensive Rats
Hypertension, August 1, 2002; 40(2): 168 - 174.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
B. J Wilkins and J. D Molkentin
Calcineurin and cardiac hypertrophy: Where have we been? Where are we going?
J. Physiol., May 15, 2002; 541(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. C. Sanguinetti
Reduced Transient Outward K+ Current and Cardiac Hypertrophy: Causal Relationship or Epiphenomenon?
Circ. Res., March 22, 2002; 90(5): 497 - 499.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. F. Bueno, B. J. Wilkins, K. M. Tymitz, B. J. Glascock, T. F. Kimball, J. N. Lorenz, and J. D. Molkentin
Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice
PNAS, March 19, 2002; (2002) 72647999.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. A. Hill, B. Rothermel, K.-D. Yoo, B. Cabuay, E. Demetroulis, R. M. Weiss, W. Kutschke, R. Bassel-Duby, and R. S. Williams
Targeted Inhibition of Calcineurin in Pressure-overload Cardiac Hypertrophy. PRESERVATION OF SYSTOLIC FUNCTION
J. Biol. Chem., March 15, 2002; 277(12): 10251 - 10255.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
O. F Bueno, E. van Rooij, J. D Molkentin, P. A Doevendans, and L. J De Windt
Calcineurin and hypertrophic heart disease: novel insights and remaining questions
Cardiovasc Res, March 1, 2002; 53(4): 806 - 821.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. L. Peterson
Pressure overload hypertrophy and congestive heart failure: Where is the "Achilles' heel"?
J. Am. Coll. Cardiol., February 20, 2002; 39(4): 672 - 675.
[Full Text] [PDF]


Home page
CirculationHome page
G. W. Dorn II
Calcineurin Inhibition in Hypertrophy : Back From the Dead!
Circulation, July 3, 2001; 104(1): 9 - 11.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
O. F. Bueno, B. J. Wilkins, K. M. Tymitz, B. J. Glascock, T. F. Kimball, J. N. Lorenz, and J. D. Molkentin
Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice
PNAS, April 2, 2002; 99(7): 4586 - 4591.
[Abstract] [Full Text] [PDF]